Alecta Tjanstepension Omsesidigt Purchases 246,000 Shares of Johnson & Johnson $JNJ

Key Points

• Alecta Tjanstepension Omsesidigt increased its Johnson & Johnson stake by 40.5% in the second quarter, buying 246,000 shares to reach 853,100 shares valued at approximately $216.7 million.
• Johnson & Johnson reported quarterly EPS of $2.90 and revenue of $25.31 billion, beating analyst expectations while revenue rose 6.6% year over year. The stock opened at $262.43, near its 12-month high of $274.90.
• The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.0% annualized yield, while analysts maintained a generally positive outlook with a “Moderate Buy” consensus rating and a $268.22 average price target.

Alecta Tjanstepension Omsesidigt raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 40.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 853,100 shares of the company's stock after purchasing an additional 246,000 shares during the period. Alecta Tjanstepension Omsesidigt's holdings in Johnson & Johnson were worth $216,653,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its position in Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock valued at $49,740,362,000 after buying an additional 3,731,074 shares during the period. State Street Corp increased its position in shares of Johnson & Johnson by 1.3% in the fourth quarter. State Street Corp now owns 133,869,843 shares of the company's stock valued at $27,704,364,000 after acquiring an additional 1,663,782 shares during the period. Auto Owners Insurance Co raised its stake in shares of Johnson & Johnson by 22,225.6% during the fourth quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company's stock valued at $1,436,633,000 after acquiring an additional 69,108,368 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Johnson & Johnson by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company's stock worth $11,967,947,000 after purchasing an additional 1,738,292 shares during the period. Finally, Norges Bank bought a new stake in shares of Johnson & Johnson in the fourth quarter worth about $6,924,523,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the firm's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at $5,779,963.81. This trade represents a 50.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Kathryn E. Wengel sold 10,000 shares of the business's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president directly owned 114,288 shares in the company, valued at $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 48,972 shares of company stock worth $12,295,205. Insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

JNJ opened at $262.43 on Tuesday. The stock has a fifty day simple moving average of $252.52 and a two-hundred day simple moving average of $241.60. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a market cap of $632.43 billion, a price-to-earnings ratio of 30.41, a price-to-earnings-growth ratio of 2.48 and a beta of 0.24. Johnson & Johnson has a 12-month low of $173.33 and a 12-month high of $274.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm had revenue of $25.31 billion for the quarter, compared to analysts' expectations of $25.06 billion. During the same quarter in the previous year, the business posted $2.77 EPS. The company's quarterly revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts predict that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Analyst Ratings Changes

A number of brokerages recently commented on JNJ. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $282.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 16th. HSBC set a $290.00 target price on shares of Johnson & Johnson and gave the stock a "buy" rating in a research report on Monday, July 6th. Weiss Ratings raised shares of Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 24th. Finally, Guggenheim boosted their price target on shares of Johnson & Johnson from $270.00 to $287.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average price target of $268.22.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source